{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:14:49Z","timestamp":1781104489560,"version":"3.54.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma, with increasing incidence, in Japan. It is associated with substantial economic burden and relatively poor survival outcomes for relapsed\/ refractory (r\/r) DLBCL patients. Despite its association with economic burden and the relatively limited number of eligible patients in Japan as reported in previous real-world studies, Japanese clinical guidelines recommend stem-cell transplantation (SCT) for transplant-eligible r\/r DLBCL patients. This is the first study to elucidate the total healthcare cost, associated cost drivers and healthcare resource use of SCT among patients with r\/r DLBCL in a nationwide setting. The study design included a follow-up period of up to 24 months with subsequent lines of therapies using retrospective nationwide claims data from the Medical Data Vision Co., Ltd. Health Insurance Association from April 2012 to August 2022. Included patients had a confirmed diagnosis of DLBCL, received allogeneic SCT (allo-SCT) or autologous SCT (ASCT) after the first DLBCL diagnosis, and received high-dose chemotherapy during the 6-month\u00a0look-back\u00a0period. The results confirmed that no patients had allo-SCT, hence only ASCT was included in the analysis. Structural equation modeling was used to identify potential total healthcare cost drivers by evaluating direct, indirect, and total effects and provide a benchmark reference for future innovative therapies. A total of 108 patients (3.8%) among all DLBCL patients who received SCT met the eligibility criteria and were considered ASCT patients; majority of which were males (n\u2009=\u200963, 58.33%), with a mean [median] (SD) age of 52.04 [55] (9.88) years. A total of 15 patients (13.89%) received subsequent therapies. The most frequent subsequent therapy was GDP-based with or without rituximab (n\u2009=\u20098, 7.41%). The mean [median] (SD) number of follow-up hospitalizations on or after SCT-related hospitalizations was 1.66 [1] (1.36), with a mean [median] (SD) length of hospital stay being 36.88 [34] (12.95) days. The total mean [median] (SD) healthcare cost after adjustment incurred per patient per year during follow-up was $79,052.44 [$42,722.82] ($121,503.65). Number of hospitalizations and Charlson Comorbidity Index scores (+5) were the key drivers of total healthcare costs in patients with r\/r DLBCL. Index years 2020\u20132022 and heart disease as a complication were other statistically significant factors that had positive effects as increase on total healthcare costs.<\/jats:p>","DOI":"10.1371\/journal.pone.0317439","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T19:00:15Z","timestamp":1738868415000},"page":"e0317439","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost drivers associated with autologous stem-cell transplant (ASCT) in patients with relapsed\/refractory diffuse large B-cell lymphoma in a Japanese real-world setting: A structural equation model (SEM) analysis 2012\u20132022"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8412-8778","authenticated-orcid":true,"given":"Saaya","family":"Tsutsu\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Asou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Shi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilinuer","family":"Ainiwaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Idehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sona-Sanae","family":"Aoyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"issue":"1","key":"pone.0317439.ref001","first-page":"5","article-title":"Epidemiology of non-Hodgkin\u2019s lymphoma","volume":"9","author":"KC Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"3","key":"pone.0317439.ref002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"pone.0317439.ref003","doi-asserted-by":"crossref","first-page":"e0237509","DOI":"10.1371\/journal.pone.0237509","article-title":"Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma","volume":"15","author":"S Tsutsu\u00e9","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"pone.0317439.ref004","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"D Chihara","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"pone.0317439.ref005","doi-asserted-by":"crossref","first-page":"e0269169","DOI":"10.1371\/journal.pone.0269169","article-title":"Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: a structural equation model (SEM) analysis","volume":"17","author":"S Tsutsu\u00e9","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"pone.0317439.ref006","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s12185-018-2430-6","article-title":"Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia\/lymphoma in Japan","volume":"107","author":"H Miyoshi","year":"2018","journal-title":"Int J Hematol"},{"key":"pone.0317439.ref007","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","author":"JW Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"pone.0317439.ref008","doi-asserted-by":"crossref","first-page":"e390802","DOI":"10.1200\/EDBK_390802","article-title":"Management considerations for patients with primary refractory and early relapsed diffuse large B-Cell lymphoma","volume":"43","author":"C Duarte","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"pone.0317439.ref009","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"LH Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"35","key":"pone.0317439.ref010","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.2217\/fon-2021-0607","article-title":"Burden of illness and outcomes in second-line large B-cell lymphoma treatment: real-world analysis of Medicare beneficiaries","volume":"17","author":"KM Kilgore","year":"2021","journal-title":"Future Oncol"},{"issue":"9","key":"pone.0317439.ref011","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","article-title":"Direct costs associated with relapsed diffuse large B-Cell lymphoma therapies","volume":"24","author":"A Purdum","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"pone.0317439.ref012","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10198-016-0775-4","article-title":"Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort","volume":"18","author":"H-I Wang","year":"2017","journal-title":"Eur J Health Econ"},{"issue":"33","key":"pone.0317439.ref013","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.2217\/fon-2021-0400","article-title":"Economic burden in treated Japanese patients with relapsed\/refractory large B-cell lymphoma","volume":"17","author":"S Tsutsu\u00e9","year":"2021","journal-title":"Future Oncol"},{"issue":"19","key":"pone.0317439.ref014","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","author":"D Sermer","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"pone.0317439.ref015","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"EA Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0317439.ref016","unstructured":"Pharmaceuticals and Medical ZDevices Agency (PMDA). List of approved cell and gene therapy products 2023 [Cited 2023 Nov 3]. Available from: https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/ctp\/0004.html"},{"key":"pone.0317439.ref017","unstructured":"Databases available for pharmacoepidemiology researches in Japan: Japanese Society for Pharmacoepidemiology; 2022 [cited 2023 Oct 25]. Available from: https:\/\/www.jspe.jp\/mt-static\/FileUpload\/files\/JSPE_DB_TF_E.pdf"},{"key":"pone.0317439.ref018","unstructured":"CSIMC. Guideline for preparing cost-effectiveness evaluation to the central social insurance medical council. 2022 [cited 2023 Sep 11]. Available from: https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf"},{"issue":"1","key":"pone.0317439.ref019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10705519909540118","article-title":"Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives","volume":"6","author":"L Hu","year":"1999","journal-title":"Structural Equation Modeling: A Multidisciplinary Journal"},{"issue":"7","key":"pone.0317439.ref020","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1080\/10428194.2020.1734592","article-title":"The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy","volume":"61","author":"J Tkacz","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"pone.0317439.ref021","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2018-0267","article-title":"Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA","volume":"14","author":"VA Morrison","year":"2018","journal-title":"Future Oncol"},{"issue":"Supplement 1","key":"pone.0317439.ref022","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2022-157309","article-title":"Hospital costs and healthcare resource utilization (HRU) for chimeric antigen (CAR) T-cell therapy and stem cell transplant (SCT) in patients with large B-cell lymphoma (LBCL) in the United States (US)","volume":"140","author":"C Cui","year":"2022","journal-title":"Blood"},{"issue":"1","key":"pone.0317439.ref023","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40487-022-00211-6","article-title":"Healthcare resource utilization and associated costs of German patients with diffuse large B-cell lymphoma: a retrospective health claims data analysis","volume":"11","author":"P Borchmann","year":"2023","journal-title":"Oncol Ther"},{"issue":"7","key":"pone.0317439.ref024","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.clml.2021.12.018","article-title":"Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): a health economic perspective","volume":"22","author":"B Moertl","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"pone.0317439.ref025","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1002\/onco.13721","article-title":"Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B-Cell lymphoma in the U.S","volume":"26","author":"X Yang","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"pone.0317439.ref026","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/healthcare8040443","article-title":"Changes and variations in death due to senility in Japan","volume":"8","author":"M Bando","year":"2020","journal-title":"Healthcare (Basel)"},{"issue":"2","key":"pone.0317439.ref027","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/onco.13610","article-title":"Challenges and opportunities in the management of diffuse large B-Cell lymphoma in older patients","volume":"26","author":"M Di","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"pone.0317439.ref028","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene ciloleucel in large B-Cell lymphoma","volume":"389","author":"JR Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0317439.ref029","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"FL Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"pone.0317439.ref030","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2217\/fon-2023-1114","article-title":"Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan","volume":"20","author":"S Tsutsu\u00e9","year":"2024","journal-title":"Future Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T19:00:27Z","timestamp":1738868427000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317439"}},"subtitle":[],"editor":[{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0317439","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}